IPSEF News and Press, Ipsen Sa Ord

Decision adds to existing collaboration agreement with Exelixis, permitting Ipsen to seek potential marketing authorizations for Cabometyx ® (cabozantinib) in advanced pancreatic and extra pancreatic neuroendocrine tumors outside of the U.S. and Japan Agreemen...

Iqirvo ® (elafibranor) 80 mg tablets is the first new medicine approved in nearly a decade for the treatment of the rare liver disease called primary biliary cholangitis Approval based on positive Phase III ELATIVE trial data Primary biliary cholan...

Using Marengo’s TriSTAR platform, Ipsen and Marengo teams expand their ongoing oncology research to include up to two additional assets in new early development collaboration Research will focus on using Marengo’s TriSTAR platform to reinvigorate and mobilize selective V...

PARIS, FRANCE, 06 June 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, announced today the appointment of Josep Catllà as EVP, Chief Corporate Affairs Officer, effective August 19, 2024. He will serve on the Executive Leadership Team (ELT) and...

New data from the ELATIVE ® Phase III trial show 70% of patients treated with elafibranor achieved composite endpoint of slowing disease progression measured by biochemical response after 78-weeks Data from the itch domain of the PBC-40 and 5-D Itch questionna...

2024-05-29 13:52:41 ET Summary Genfit S.A. has a PDUFA date of June 10, 2024, by which time the FDA will decide upon whether elafibranor should be approved to treat patients with primary biliary cholangitis. European marketing approval of elafibranor for treatment of patients with...

PARIS, FRANCE, 2 May 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, announced today the appointment of Keira Driansky as EVP, President of North America, effective May 13, 2024. She will serve on the Executive Leadership Team (ELT) and report dire...

2024-04-24 02:26:32 ET More on Ipsen S.A. Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors Ipsen, Skyhawk enter RNA targeting research collab in rare neurological diseases Ipsen secures exclusive global rights of Sutro Biopharma's STR...

PARIS, FRANCE, 24 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024. Highlights Total-sales growth of 13.3% at CER 1 , or 10.9% as reported, driven by the 16.2% ...

Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development candidate validation, Ipsen will assume responsibility for further development and commercialization, leveraging existing neuroscience expertise...